TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma
The Kaohsiung Journal of Medical Sciences · 2024
DOI: 10.1002/kjm2.12798 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2024. Verfasst von Peir-In Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kaohsiung Medical University Chung-Ho Memorial Hospital.
Abstract (Originalsprache)
Urothelial carcinoma (UC) is common cancer worldwide with a high prevalence in Taiwan, especially in the upper urinary tract, including the renal pelvis and ureter, also classifying as upper urinary tract urothelial carcinoma. Here, we aim to find a representative prognostic marker that strongly correlates to this type of carcinoma. Transforming growth factor beta‐1‐induced transcript 1 (TGFB1I1) is a cofactor of cellular TGF‐β1 and interacts with various nuclear receptors. The previous study showed that TGFB1I1 promotes focal adhesion formation, contributing to the epithelial‐mesenchymal transition (EMT) with actin cytoskeleton and vimentin through TGFB1I1 regulation. We aim to reveal the role of TGFB1I1 in the tumorigenesis of UC. In silico and clinicopathological data of upper urinary tract urothelial carcinoma (UTUC) and urinary bladder urothelial carcinoma (UBUC) were accessed and analyzed for IHC staining regarding tumor characteristics, including survival outcome. Finally, an in vitro study was performed to demonstrate the biological changes of UC cells. In UTUC, overexpression of TGFB1I1 was significantly correlated with advanced tumor stage, papillary configuration, and frequent mitosis. Meanwhile, overexpression of TGFB1I1 was significantly correlated with advanced tumor stage and histological grade in UBUC. Moreover, the in vitro study shows that TGFB1I1 affects cell proliferation, viability, migration and wound healing. The EMT markers also decreased upon TGFB1I1 knockdown. In this study, we identified that TGFB1I1 regulates UC cell proliferation and viability and induces the EMT to facilitate cell migration in vitro, leading to its essential role in promoting tumor aggressiveness in both UTUC and UBUC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Department of Pathology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Pathology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
- Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
ORCID-Profile: Peir-In Liang, Huan-Da Chen, Yu-Chun Ma, Hung-Lung Ke, Hao-Wen Chuang
Förderung
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Zitieren
APA
Liang, P. I., Wei, Y. C., Chen, H. D., Ma, Y. C., Ke, H. L., Chien, C. C., & Chuang, H. W. (2024). TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12798
Vancouver
Liang PI, Wei YC, Chen HD, Ma YC, Ke HL, Chien CC, et al. TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma. The Kaohsiung Journal of Medical Sciences. 2024. doi:10.1002/kjm2.12798
BibTeX
@article{Liang2024,
author = {Liang, Peir-In and Wei, Yu-Ching and Chen, Huan-Da and Ma, Yu-Chun and Ke, Hung-Lung and Chien, Chu-Chun and Chuang, Hao-Wen},
title = {TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2024},
doi = {10.1002/kjm2.12798}
}
EUVIMED